Despite lowering our short-term forecasts, Redeye retains its positive stance on Speqta following th...
Redeye comments on Oncopeptides' Q1 report, which had few surprises in terms of financials.
Redeye reviews the Integrum case and provides a more clear-cut take on its longer-term outlooks.
Redeye updates its estimates and valuation following Freemelt’s Q1 report, which fell below expectat...
Redeye comments on the subscription price and the strong start of the Terclara launch.
Svedbergs Group has set the course to consolidate the European market for bathroom fittings, evolvin...
Redeye comments on the Q1 report 2024. The rest of 2024 is funded through the recent rights issue, i...
PTS has published new statistics for the SE fibre market BRE2 market share: slightly down versus 202...
Redeye comments on the positive outcome of Annexin’s rights issue.
Q-linea and its distribution partners continue to advance pilot and tender process activities, which...
Redeye briefly comments on CLS’ rights issue. We pause our coverage.
Redeye comments on Ngenic’s Q1 report, which was in line with the preliminary figures communicated e...
Suominen has today announced a restructuring programme that is expected to generate EUR 1.
Redeye comments on Freemelt’s Q1 results, which came in lower than expected in terms of sales due to...
No deliveries in Q1 compared to one Freemelt ONE expected Opex being kept under control despite inve...
Redeye sees a mixed Q1 report where ARR growth accelerates q/q but comes somewhat short of our expec...
We visited Borås Tapetfabrik on Wednesday We assess there is limited technological risk for traditio...
The SEK48m loan from Swedish Energy Agency is converted into grant.
Syncro Group har publicerat koncernens delårsrapport för det första kvartalet 2024.
Försäljningstrenden fortsätter Nettoomsättningen i kvartalet ökade med hela 114,0 procent.
